Dr. Paul Harmatz
Claim this profileUniversity of California San Francisco, Benioff Children's Hospital
Expert in Mucopolysaccharidosis
Studies Hunter Syndrome
15 reported clinical trials
18 drugs studied
Area of expertise
1Mucopolysaccharidosis
Global LeaderIDS positive
I2S
GAGs
2Hunter Syndrome
IDS positive
I2S
GAGs
Affiliated Hospitals
Clinical Trials Paul Harmatz is currently running
ELAPRASE + Prophylactic Therapy
for Hunter Syndrome
The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter syndrome. In this open label, single arm study, all participants will receive ELAPRASE treatment and a prophylactic ITR. Participants will be treated with ELAPRASE for up to 104 weeks. The prophylactic ITR will start 1 day prior to the start of ELAPRASE. The prophylactic ITR will consist of a 5-week cycle of: Rituximab (intravenously \[IV\], weekly for 4 weeks); Methotrexate (oral, 3 times per week for 5 weeks) and intravenous immunoglobulin (IVIG) (IV, every 4 weeks of the cycle). Following the completion of 1 cycle, an assessment will be made at Month 6, 12, and 18 regarding the need for administering another 5-week cycle of the ITR. Participants will be in the study for approximately 112 weeks (including 6 weeks for screening, up to 104 weeks for treatment, and 2 weeks for follow-up).
Recruiting3 awards Phase 48 criteria
Tividenofusp Alfa
for Hunter Syndrome
This trial is testing a new treatment called tividenofusp alfa for patients with a rare genetic disorder called MPS II. The treatment aims to replace missing enzymes to help break down harmful substances in the brain and body.
Recruiting1 award Phase 2 & 33 criteria
More about Paul Harmatz
Clinical Trial Related1 year of experience running clinical trials · Led 15 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Paul Harmatz has experience with
- RGX-121
- DNL310
- JR-141
- Observational
- Infigratinib
- ELAPRASE
Breakdown of trials Paul Harmatz has run
Mucopolysaccharidosis
Hunter Syndrome
Klinefelter Syndrome and Triple X Syndrome.
Sanfilippo Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paul Harmatz specialize in?
Paul Harmatz focuses on Mucopolysaccharidosis and Hunter Syndrome. In particular, much of their work with Mucopolysaccharidosis has involved IDS positive patients, or patients who are I2S.
Is Paul Harmatz currently recruiting for clinical trials?
Yes, Paul Harmatz is currently recruiting for 4 clinical trials in Oakland California. If you're interested in participating, you should apply.
Are there any treatments that Paul Harmatz has studied deeply?
Yes, Paul Harmatz has studied treatments such as RGX-121, DNL310, JR-141.
What is the best way to schedule an appointment with Paul Harmatz?
Apply for one of the trials that Paul Harmatz is conducting.
What is the office address of Paul Harmatz?
The office of Paul Harmatz is located at: University of California San Francisco, Benioff Children's Hospital, Oakland, California 94609 United States. This is the address for their practice at the University of California San Francisco, Benioff Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.